Topic
Topic
Pfizer's tilrekimig produced Phase II skin clearance in atopic dermatitis and is positioned for a direct head-to-head against dupilumab, the IL-4/IL-13 incumbent that defines the moderate-to-severe e…
Pfizer's investigational IL-17 inhibitor tilrekimig produced a significant skin clearance signal in a Phase 2 atopic dermatitis t…
Tilrekimig, a first-in-class trispecific antibody targeting IL-4, IL-13 and TSLP, delivered EASI-75 rates up to 62.5% at Week 16…
Pfizer has disclosed Phase 2 atopic dermatitis results for tilrekimig, its mid-stage candidate; detailed efficacy and safety data…
Pfizer reports its investigational tilrekimig achieved significant skin clearance in a Phase 2 atopic dermatitis study, advancing…
Pfizer advances tilrekimig into pivotal atopic dermatitis and asthma trials on the strength of Phase II AD data, deepening its ty…
